OncoMatch/Clinical Trials/NCT06097468
Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
Is NCT06097468 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies NisinZ® P for oral cavity squamous cell carcinoma.
Treatment: NisinZ® P — This is a study of oral nisin administration in patients with OSCC who are undergoing complete surgical resection surgery with or without adjuvant radiation/chemoradiation as part of their routine care at the University of California, San Francisco (UCSF).
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Excluded: HPV DNA positive
history of a known positive human papillomavirus deoxyribonucleic acid ((HPV DNA) test (P16-positive is permitted if HPV DNA test is negative)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic anticancer therapy
Exception: prior immunotherapy is permitted both prior to enrollment and concurrent with study participation
Individuals who require treatment with a systemic anticancer therapy prior to enrollment, with the exception of prior immunotherapy which is permitted both prior to enrollment and concurrent with study participation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify